Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Filippo de Marinis | Researchclopedia

Back to researchers

Filippo de Marinis

Istituto Oncologico Veneto ORCID

725

Works

46,083

Citations

79

h-index

313

i10-index

Research Topics

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Lung Cancer Diagnosis and Treatment

Affiliations

Universidade da Coruña2017–2017

Ontario Institute for Cancer Research2004–2023

University of Messina2017–2017

Tongji University2017–2017

University of Verona2017–2017

Top Works

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell,Enric Carcereny,et al.

20125,500 citations

Colorectal Cancer Treatments and Studies

Cancer Immunotherapy and Biomarkers

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer,Fabrice Barlési,et al.

20164,729 citations

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Giorgio V. Scagliotti,Purvish Parikh,et al.

20083,206 citations

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

Nasser H. Hanna,Frances A. Shepherd,et al.

20042,425 citations

Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer

Yi‐Long Wu,Masahiro Tsuboi,et al.

20201,694 citations

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Roy S. Herbst,Giuseppe Giaccone,et al.

20201,644 citations

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

Robert Pirker,Jose R. Pereira,et al.

20091,355 citations

First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer

Alice T. Shaw,Todd M. Bauer,et al.

20201,033 citations

Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer

Jürgen Wolf,Takashi Seto,et al.

2020978 citations